Literature DB >> 3114368

Elevated titers of cell-free interleukin 2 receptor in serum of lupus mice.

R S Balderas, O Josimovic-Alasevic, T Diamantstein, F J Dixon, A N Theofilopoulos.   

Abstract

Activation/proliferation of mouse and human T and B cells is associated with expression and subsequent release of interleukin 2 receptors (IL 2R) into the milieu. The soluble form of IL 2R, at least in part, retains its ability to bind to IL 2 and to anti-receptor antibodies, but its exact structure remains unknown. Because systemic lupus erythematosus (SLE) is associated with T and B cell activation, we have used monoclonal anti-IL 2R antibodies in an ELISA to measure levels of IL 2R in sera of various lupus strains. High levels of the released receptor were found at an active clinical stage in sera of four autoimmune strains of mice homozygous for the lpr (lymphoproliferation) gene that causes T cell expansion, massive lymphoid organ enlargement, and promotes the autoimmune process. High levels were also found in lupus mice characterized primarily by B cell proliferation (BXSB males) and in (NZB X W)F1 mice characterized by T and B cell activation. Similarly high IL 2R serum levels could be induced experimentally in normal mice injected with immunostimulants such as bacterial lipopolysaccharide or Freund's complete adjuvant. The results indicate that IL 2R serum levels may provide a good marker of ongoing lymphoid cell activation/proliferation, and thus might be useful in the follow-up of patients with systemic autoimmune or other lymphoproliferative disorders. The biologic roles, if any, of the soluble form of IL 2R and its effects in normal and abnormal conditions remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114368

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus.

Authors:  Y Tokano; A Murashima; Y Takasaki; H Hashimoto; K Okumura; S Hirose
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus.

Authors:  P Airŏ; S Braga; E Prati; D Brugnoni; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

3.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

4.  The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.

Authors:  H D Volk; O Josimovic-Alasevic; M Gross; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

5.  Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?

Authors:  R Meliconi; E Lalli; R M Borzì; C Sturani; V Galavotti; G Gunella; R Miniero; A Facchini; G Gasbarrini
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

6.  Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis.

Authors:  G Famularo; A Procopio; R Giacomelli; C Danese; S Sacchetti; M A Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

7.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  Serum soluble interleukin 2 receptor in systemic lupus erythematosus: effects of disease activity and infection.

Authors:  K L Wong; R P Wong
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

9.  Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus.

Authors:  E Kling; S Bieg; M Boehme; W A Scherbaum
Journal:  Clin Investig       Date:  1993-04

10.  Interleukin 2 receptor in patients with localized and systemic parasitic diseases.

Authors:  O Josimovic-Alasevic; H Feldmeier; K Zwingenberger; G Harms; H Hahn; M Shrisuphanunt; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.